Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B001 Injection in Aquaporin-4 Antibody Positive Patients With Neuromyelitis Optica Spectrum Disorder

NCT06413654 is registered in ClinicalTrials.gov with Shanghai Jiaolian Drug Research and Development Co., Ltd as lead sponsor.

NCT NCT06413654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06413654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B001 Injection in Aquaporin-4 Antibody Positive Patients With Neuromyelitis Optica Spectrum Disorder
Lead sponsor
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase
Phase 2/3
Overall status
Recruiting
Start date
July 17, 2024
Completion date
February 28, 2029
Enrollment
132 (estimated)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

neuromyelitis optica spectrum disorders